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Abstract
Background: Asymmetric dimethylarginine (ADMA), present in human serum, is an endogenous inhibitor of nitric oxide
synthase and contributes to vascular disease. Dimethylarginine dimethylaminohydrolase (DDAH) is an ADMA degrading
enzyme that has two isoforms: DDAHI and DDAHII. We sought to determine whether serum ADMA levels in type 2 diabetes
are influenced by common polymorphisms in the DDAH1 and DDAH2 genes.
Methodology/Principal Findings: Relevant clinical parameters were measured and peripheral whole blood obtained for
serum and genetic analysis on 343 participants with type 2 diabetes. Serum ADMA concentrations were determined by
mass spectroscopy. Twenty six tag SNPs in the DDAH1 and 10 in the DDAH2 gene were genotyped in all subjects and tested
for association with serum ADMA levels. Several SNPs and haplotypes in the DDAH genes were strongly associated with
ADMA levels. Most significantly in the DDAH1 gene, rs669173 (p=2.96610
27), rs7521189 (p=6.40610
27), rs2474123
(p=0.00082) and rs13373844 (p=0.00027), and in the DDAH2 gene, rs3131383 (p=0.0029) and the TGCCCAGGAG
haplotype (p=0.0012) were significantly associated with ADMA levels. Sub-analysis by diabetic retinopathy (DR) status
revealed these variants were associated with ADMA levels predominantly in participants without DR. Combined analysis of
the most strongly associated SNPs in DDAH1 (rs669173) and DDAH2 (rs3131383) revealed an additive effect (p=1.37610
28)
on ADMA levels.
Conclusions/Significance: Genetic variation in the DDAH1 and 2 genes is significantly associated with serum ADMA levels.
Further studies are required to determine the pathophysiological significance of elevated serum ADMA in type 2 diabetes
and to better understand how DDAH gene variation influences ADMA levels.
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Introduction
Asymmetric dimethylarginine (ADMA) is an endogenous
inhibitor of nitric oxide synthase (NOS), the key endothelial
enzyme that converts L-arginine to L-citrulline and nitric oxide
(NO). Endothelium-derived NO helps to maintain vascular
homeostasis through vasodilatation, suppression of inflammation
and inhibition of the proliferation of vascular smooth muscle cells
[1,2], platelet adhesion and aggregation [3,4].
ADMA levels have been shown to be increased in individuals
with diabetes mellitus [5]. Endothelial dysfunction, such as occurs
in hyperglycemia, is associated with decreased NOS activity and
NO bioavailability resulting in vasoconstriction and increased
reactive oxygen species. This leads to impaired ocular hemody-
namics [6]. Recently, elevated serum ADMA in both diabetes [5]
and its complications, including retinopathy [7,8,9,10] and
nephropathy [10,11], have been reported.
Dimethylarginine dimethylaminohydrolase (DDAH) is the
enzyme responsible for the degradation of ADMA into citrulline
and dimethylamine [12,13]. Over 90% of endogenous ADMA is
metabolised by DDAH with the remainder renally excreted [14].
DDAH is expressed as two isoforms encoded by different genes.
DDAHI predominates in tissues expressing neuronal NOS
(nNOS), and is encoded by the DDAH1 (OMIM#604743) gene
on chromosome 1p22. DDAHII is found in highly vascular tissues
expressing endothelial NOS (eNOS) [15,16], and immune tissues
expressing inducible NOS (iNOS) [16], and is encoded by the
DDAH2 (OMIM#604744) gene on chromosome 6p21.3.
Evidence for the metabolic control of ADMA by DDAH genes,
and their influence on endothelial cells has been provided by
animal studies. DDAH1 overexpressing transgenic mice had a two
fold reduction in plasma ADMA associated with a 2 fold increase
in tissue NOS activity [17]. Conversely, DDAH1 knockout mice
had increased pulmonary endothelial permeability as a result of
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9462ADMA elevation, which was prevented by overexpression of
DDAH1 and DDAH2 in endothelial cells [18].
We aimed to determine whether serum ADMA levels are
influenced by common single nucleotide polymorphisms (SNPs) in
DDAH1 and DDAH2 genes in a large Australian cohort of
individuals with type 2 diabetes, and found that genetic variation
in the DDAH1 and DDAH2 genes significantly and additively
affects serum ADMA concentrations.
Results
Three hundred and forty three participants with type 2 diabetes
were included. Disease duration, smoking, nephropathy and
diabetic retinopathy were significantly associated with serum
ADMA levels in all participants (p,0.05, Table 1). These variables
were subsequently adjusted for in multivariate analyses. Subjects
with no retinopathy (n=225) were more likely to be female, had
shorter duration of disease, significantly lower HbA1c levels and
less nephropathy when compared to subjects with blinding
diabetic retinopathy (n=118, data not shown).
Several SNPs in the DDAH genes were significantly associated
with serum ADMA levels after adjusting for associated variables in
the multivariate analyses (Table 2 and Figure 1), with the most
significant in DDAH1 being rs669173 [p=2.96610
27 in the
genotypic model, Beta coefficient (B): 20.03, 95% CI: 20.04 to
20.02], rs7521189 (p=6.40610
27 in the additive model, B:
20.03, 95% CI: 20.04 to 20.01), rs2474123 (p=0.00082 in the
additive model, B: 0.02, 95%CI: 0.01–0.04), rs13373844
(p=0.00027 in the dominant model, B: 20.03, 95% CI: 20.05
to 20.02) and rs986639 (p=0.0015 in the genotypic model, B:
0.03, 95% CI: 0.01–0.05). The SNPSpD method for multiple
testing correction in SNP association studies estimated a total of 17
independent tests for DDAH1 analyses and after correcting for
multiple testing, the SNPs listed above remained significantly
associated with serum ADMA levels (p,0.03, Table 2).
SNP rs3131383 in DDAH2 was significantly associated with
serum ADMA levels (p=0.0029 in the dominant model, B: 20.03,
95% CI: 20.06 to 20.01, Table 2 and Figure 1). Seven
independent tests for DDAH2 were estimated by the SNPSpD
method and after correcting for multiple testing, rs3131383
(p=0.034 in the dominant model) remained significantly associ-
ated with ADMA levels in all participants (Table 2).
Sub-analysis by diabetic retinopathy status in the multivariate
analyses revealed the majority of these SNPs to be associated with
ADMA level only in the subgroup of participants that had no
diabetic retinopathy, most significantly rs669173 (p=4.66610
25 in
the additive model, B: 20.05, 95% CI: 20.08 to 20.03), rs2474123
(p=0.00086 in the additive model, B: 0.04, 95% CI: 0.01–0.06) and
rs7521189 (p=0.0027 in the additive model, B: 20.03, 20.06 to
20.01, Table 2). These SNPs remained significant after correction
for multiple testing. In the blinding diabetic retinopathy cases,
rs669173 (p=0.017 in the additive model), and rs7521189
(p=0.023 in the additive model) were nominally significant,
however did not survive correction for multiple testing (Table 2).
Althoughassociationofrs3131383inDDAH2withADMAlevelwas
not statistically significantly associated in the smaller blinding
retinopathy group, the direction of the association with ADMA was
the same as that for no retinopathy controls and the full dataset
(p=0.143, B: 20.03 95% CI: 20.07–0.01).
To assess whether there are additive effects of polymorphisms in
the two genes on serum ADMA, the total number of minor alleles
of the most significantly associated SNP in each gene (rs669173
and rs3131383) was counted in each individual and included in the
linear regression along with the clinical covariates. Multiple minor
alleles were associated with lower serum ADMA (Supplementary
Table S1B). The total number of minor alleles of the two SNPs
was significantly associated with ADMA serum level after
adjusting for relevant clinical variables (p=1.37610
208,B :
20.03, 95% CI: 20.04 to 20.02, Table 3). This model accounted
for more of the variation (r
2=0.147) than including each SNP in
the regression as a separate factor with (r
2=0.119) or without
(r
2=0.119) an interaction term between the two SNPs. Thus the
two genes appear to influence ADMA levels additively.
For the haplotype analyses, observation of the DDAH SNPs in
HapMap revealed three blocks of linkage disequilibrium in DDAH1
and one block in DDAH2 (Table 4). As block 2 of DDAH1 consisted
of 11 tag SNPs, it was further subdivided into two blocks for the
haplotype analyses. After adjusting for associated variables in the
multivariate analyses, several DDAH1 haplotypes were significantly
associatedwithADMAlevels,withthe GAATTT haplotypeofblock
2A (p=0.00012, B: 20.03, 95% CI: 20.04 to 20.01, Table 4 and
Figure 1), and the TATAGTGGAG haplotype of block 3
(p=0.00074, B: 20.02, 95% CI: 20.04 to 20.01) being the most
significantly associated (Table 4). The TGCCCAGGAG of DDAH2
was significantly associated with serum ADMA levels (p=0.0012 B:
Table 1. Clinical characteristics [number of subjects (%) or mean6standard deviation] of all participants and associations with
serum ADMA levels.
Clinical characteristics All participants (n=343) Pearson Correlation P value
Female (%) 162 (47) 20.054 0.316
Age (years) 63.7612.9 0.006 0.914
Disease duration (years) 14.868.9 0.138 0.011
HbA1c (%) 7.961.8 0.099 0.098
BMI (kg/m2) 32.367.2 0.074 0.182
Hypercholesterolemia (%) 249 (70) 20.019 0.728
Smoker (%) 178 (52) 0.115 0.033
Retinopathy (%) 118 (35) 0.115 0.034
Nephropathy (%) 95 (28) 0.111 0.041
GFR (mL/min) 121.56407.4 0.022 0.702
Hypertension (%) 285 (83) 0.050 0.352
doi:10.1371/journal.pone.0009462.t001
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haplotypesremainedsignificantafterBonferronicorrection(Table4).
Sub-analysis by diabetic retinopathy status revealed 5 of these
haplotypesinDDAH1 and the single associated haplotype inDDAH2
to be significantly associated with serum ADMA level in the no
diabetic retinopathy subgroup (Table 4) in the multivariate analyses.
No haplotypes were associated with ADMA level in the blinding
diabetic retinopathy subgroup after correction for multiple testing.
Discussion
This study found genetic variation in the DDAH1 and DDAH2
genes to be significantly associated with serum ADMA levels in
participants with type 2 diabetes. To our knowledge, this is the first
study of its kind to investigate genetic variation in DDAH genes
and their association with serum ADMA levels in patients with
type 2 diabetes.
Table 2. Association of DDAH tag SNPs and with serum ADMA levels in all participants.
Additive Genotypic Dominant Recessive
SNP # SNP name Minor allele P value P value P value P value
DDAH1 1 rs17590006 G 0.0509 0.0109{ 0.0037{ 0.1331
2 rs1498373 T 0.0122{ 0.0171{ 0.0129 0.0459
3 rs233130 G 0.0067{ 0.0082{ 0.0063{ 0.0320{
4 rs233080 A 0.4799 0.5185 0.6694 0.3679
5 rs2474123 A 0.0008*{ 0.0024{ 0.0032{ 0.0095{
6 rs986639 C 0.0020*{ 0.0015*{ 0.0093{ 0.0034{
7 rs12132677 C 0.3125 0.2603 0.1188 0.3919
8 rs7521189 A 6.40E-07*{ 3.08E-06*{ 0.0073 2.29E-05*{
9 rs17388437 C 0.2117 0.4512 0.9184 0.2106
10 rs11161614 G 0.1651 0.0799 0.0312 0.2791
11 rs553257 C 0.2730 0.4311 0.2995 0.3152
12 rs669173 C 8.52E-07*{ 2.96E-07*{ 0.0006*{ 8.48E-06*{
13 rs539714 C 0.0397 0.0957 0.3206 0.0423
14 rs11161618 T 0.1986 0.3762 0.1887 0.3788
15 rs2935 A 0.0402{ 0.0354{ 0.0448 0.0457{
16 rs13373844 C 0.0065{ 0.0007{ 0.0003*{ 0.0447
17 rs3738111 C 0.4493 0.4404 0.4608 0.4253
18 rs877041 A 0.3845 0.5145 0.2565 0.6132
19 rs12568675 C 0.0080{ 0.0086{ 0.0223 0.0102{
20 rs974874 C 0.2716 0.5220 0.4315 0.3135
21 rs480414 A 0.7295 0.9286 0.7453 0.7703
22 rs1241321 C 0.2872 0.3422 0.1526 0.4686
23 rs587843 C 0.9023 0.7975 0.5345 0.9364
24 rs10782551 A 0.9029 0.1900 0.0844 0.8544
25 rs1403955 C 0.1959 0.3157 0.1524 0.3582
26 rs1403951 T 0.3152 0.4972 0.2431 0.5851
DDAH2 1 rs805287 C 0.4247 0.7155 0.5545 0.4719
2 rs6916278 A 0.9751 0.9945 0.9164 0.9786
3 rs805285 G 0.1883 0.4166 0.5521 0.1905
4 rs15574 T 0.2355 0.3790 0.9151 0.1986
5 rs805294 C 0.4001 0.6263 0.3565 0.5493
6 rs805293 T 0.7413 0.9147 0.9231 0.6761
7 rs9267551 C 0.6374 0.5282 0.2590 0.6907
8 rs2272592 A 0.2848 0.4027 0.2462 0.3306
9 rs3131383 A 0.0179{ 0.0038*{ 0.0029*{ 0.0272{
10 rs3131382 A 0.5141 0.8071 0.7988 0.5127
Note: p values have been adjusted for duration of diabetes, age, hypertension, smoking, nephropathy and retinopathy status. Results are shown only if genotypes were
carried by 5 or more participants. Significant p values are shown in bold type.
* = p-values survive correction for multiple testing.
{ = p values are also significant in no diabetic retinopathy subset.
doi:10.1371/journal.pone.0009462.t002
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bioavailability. The role of NO in the development of insulin
resistance is supported by eNOS [19,20] and nNOS [20] knockout
mice studies. Similarly, previous studies have shown serum ADMA
elevation to be significantly associated with diabetes [5] and insulin
resistance [21] in humans. Animal studies have also supported the
role of ADMA in insulin resistance, with DDAH expression shown
to play a role [22]. When compared to wild type mice, in response
to a glucose challenge, Sydow et al found DDAH1 transgenic mice
to show a blunted increase in ADMA, plasma insulin and glucose
[22]. Hyperglycemia has also been shown to lead to decreased
DDAH activity and subsequent ADMA elevation [23]. A variety
of other factors have also been shown to be involved in control of
DDAH expression and activity. For example, oxidative stress and
inflammation in cultured human endothelial cells decreases
DDAH activity and upregulates ADMA synthesis [24,25]
subsequently leading to a reduction in NO synthesis [26].
Variation in the promoter region of DDAH2 influences its
Figure 1. Idiogram of significantly associated SNPs and haplotypes of DDAH I (1A) and DDAH II (1B) with serum ADMA levels. Scales
of genomic regions are estimates. P values are presented for significant SNPs and haplotype associations have been adjusted for disease duration,
age, hypertension, smoking, nephropathy and diabetic retinopathy.
doi:10.1371/journal.pone.0009462.g001
Table 3. Association of the combination of the most significantly associated DDAH1 (rs669173) and DDAH2 (rs3131383) SNPs with
serum ADMA levels in all participants.
Variable B Lower 95% CI Upper 95% CI P value
Combined DDAH1 and 2 SNPs 20.03 20.04 20.02 1.37610
208
Disease duration 0.00 0.00 0.00 0.006
Age 0.00 0.00 0.00 0.319
Hypertension 0.01 20.01 0.03 0.431
Smoking 0.02 0.01 0.04 0.011
Nephropathy 0.01 0.00 0.03 0.144
DR 0.01 0.00 0.03 0.121
(Constant) 0.73 0.66 0.81
B=beta coefficient.
doi:10.1371/journal.pone.0009462.t003
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DDAH2 expression in cultured rat aortic endothelial cells,
indicating a possible positive feedback mechanism [28].
NO is also a key player in protection against microvascular
damage [6], and serum ADMA levels have been found to be
increased in conditions associated with endothelial dysfunction,
including hypertension, hypercholesterolemia, hyperhomocystei-
nemia [29,30] and diabetic retinopathy [7,8,9,10]. Although
DDAHI is primarily expressed in tissues producing nNOS [15,16]
and DDAHII in tissues producing eNOS and iNOS [16], all three
isoforms of NOS have been isolated from the retina [31,32,33,34].
Decreased retinal expression of eNOS [31] and increased
expression of iNOS [32,33] and nNOS [34] have been shown to
be associated with hyperglycemia and diabetic retinopathy in both
animal and human studies.
ADMA is present in the aqueous humor of the human eye. In a
recent proteomic study with relatively small numbers, aqueous
humor and serum ADMA levels were significantly higher in
subjects with diabetes and those with severe diabetic retinopathy
when compared to non-diabetic controls [9]. Sub-analysis by
Table 4. Association of common DDAH haplotypes (.2% frequency) with ADMA levels.
DDAH gene Haplotype block Haplotype Haplotype frequency P value
1 Block 1 ACAGG 0.055 0.0483
(SNPs 1–5) ACAGA 0.091 0.2800
GCAGG 0.236 0.0027*{
ACAAG 0.287 0.9190
ATGGA 0.326 0.0023*{
1 Block 2A CAGTGT 0.034 0.1410
(SNPs 6–11) GAGCTT 0.035 0.6610
GCGTGT 0.084 0.6920
CCGTGT 0.098 0.0044*
GAATTC 0.187 0.3250
GAGTTT 0.256 0.0139
GAATTT 0.279 0.0001*{
1 Block 2B CTCGC 0.051 0.0252
(SNPs 12–16) TTCAA 0.091 0.0203
TTCGA 0.124 0.0934
TCCGA 0.144 0.1960
CTCGA 0.149 0.0844
TTTGA 0.193 0.0561
CTTGC 0.224 0.0030*{
1 Block 3 TATAGTGGAG 0.276 0.0007*{
(SNPs 17–26) TACAGCGGAG 0.093 0.0041*
TGTAACCAAG 0.084 0.0553
TGTAGTCGAG 0.036 0.2330
TGTAACCGCT 0.101 0.2830
TGTCGTGGCT 0.260 0.5820
TGTAACGGAG 0.027 0.8180
CGTAATCGAT 0.080 0.9550
2 Block 1 CGCCTTGGCG 0.043 0.8070
(All SNPs) TGCCTACACA 0.052 0.3660
TGCCTACACG 0.052 0.2750
TGCCTAGACG 0.054 0.9140
CGGCCAGGCG 0.064 0.3470
TACCTTGGCG 0.067 0.9030
TGCCCAGGAG 0.111 0.0012*{
CGGTCAGGCG 0.199 0.9650
TGCCTTGGCG 0.348 0.8960
Note: SNPs correspond to the order of those shown in Table 2. P values have been adjusted for duration of diabetes, age, hypertension, smoking, nephropathy and
retinopathy status. Significant p values are shown in bold type.
* = p values survive correction for multiple testing.
{ 0= p values are also significant in no diabetic retinopathy subset.
doi:10.1371/journal.pone.0009462.t004
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levels to be associated with common genetic variation in DDAH
genes, primarily in our cohort of individuals with type 2 diabetes
without diabetic retinopathy. However, for the mostly significantly
associated SNPs, the serum ADMA levels trend in the same
direction, and a true association may exist in the smaller
retinopathy cohort which is less powered to detect the effect.
The participants with no diabetic retinopathy had significantly
lower ADMA levels compared to those with diabetic retinopathy
[10]. Although the lack of highly significant association in the
retinopathy group is likely attributable to power, it is possible that
other influences play a greater role in determining serum ADMA
levels once microvascular damage has occurred. Impairment of
ADMA metabolism may occur due to oxidative stress and
inflammation involved in endothelial dysfunction and microvas-
cular damage. However, some studies have found elevated retinal
NO in proliferative diabetic retinopathy [35], therefore ADMA
elevation may actually be a compensatory mechanism to decrease
pathologically elevated NO. It remains unclear whether ADMA
elevation in diabetic retinopathy is a causal association or occurs as
a result of endothelial dysfunction, and these potential mechanisms
are not mutually exclusive.
Diabetic retinopathy is a debilitating complication of diabetes
mellitus with a multifactorial pathogenesis and limited treatment
options. Further prospective and functional studies investigating
the pathophysiological significance of elevated serum ADMA in
the development of diabetic retinopathy and other diabetes
complications are required. Ultimately, if causal relationships are
established, this could lead to design of future therapeutic or
preventative strategies to correct NO levels in the ocular
environment, thereby retarding or preventing the development
of diabetic retinopathy.
Many of the most significantly associated DDAH1 SNPs in this
study are located in intron 1 of the gene. The significantly
associated DDAH2 SNP (rs3131383), although within the block of
linkage disequilibrium that contains DDAH2, is actually within the
chloride intracellular channel 1 (CLIC1) gene and 6255 bp from
the DDAH2 transcription start site. CLIC1 encodes chloride ion
channels that regulate fundamental cellular processes including
transepithelial transport, maintenance of intracellular pH, and
regulation of cell volume and cell cycle [36,37,38]. No associations
have been reported between CLIC1 and serum DDAH or ADMA.
The associated SNPs in both genes could either tag functional
SNPs that affect expression level (eg promoter or other regulatory
variants), or coding variants that affect DDAH protein activity.
Very few if any common coding variants have been reported in
these genes and therefore deep resequencing may be required to
determine if they do exist.
In conclusion, genetic variation in DDAH1 and DDAH2 genes
was found to be strongly and significantly associated with serum
ADMA levels in patients with type 2 diabetes, especially in those
without retinopathy. Further studies are required to assess DDAH
sequence variation and its influence on DDAH activity and serum
ADMA levels both in individuals with and without diabetes to
increase understanding of this complex pathway in normal and
pathogenic conditions.
Methods
Ethics Statement
Ethics approval was obtained from the Human Research Ethics
Committees of Flinders Medical Centre, Royal Adelaide Hospital
and Queen Elizabeth Hospital in Adelaide, Australia, and written
informed consent was obtained from all participants.
Subject Recruitment
Subjects were recruited from ophthalmology and endocrinology
outpatient clinics of three tertiary hospitals in metropolitan
Adelaide, South Australia, initially to study the genetics of blinding
diabetic retinopathy. Participants were over 18 years of age and
were required to have type 2 diabetes of at least 5 years duration
and be on oral hypoglycemic or insulin therapy.
A detailed questionnaire containing information regarding sex,
age, ethnicity, age at diagnosis of diabetes, family diabetic history,
co-existing risk factors, systemic complications of diabetes, ocular
complications as a result of diabetic retinopathy, past ocular
history, smoking history and alcohol intake was conducted in
person for each participant. Renal function tests [serum creatinine,
urine albumin and albumin:creatinine ratio and glomerular
filtration rate (GFR)], serum cholesterol and HbA1c levels were
obtained from a state-wide database. Three recent HbA1c levels
were averaged for each participant. For those cases diagnosed with
blinding DR, HbA1c levels at the time of the ocular complication
were used, and for controls with DM, HbA1c levels immediately
prior to recruitment were averaged.
Peripheral whole blood was obtained from each participant and
DNA extracted using the QiaAmp Blood Maxi Kit (Qiagen,
Valencia, CA, USA). Blood pressure and body mass index (BMI)
were measured in each participant. Patients were classified as
hypertensive if they were on treatment for hypertension, or they
had a blood pressure reading greater than or equal to 140/
90 mmHg at the time of recruitment. Hypercholesterolemia was
defined as total cholesterol of greater than 5.5 mmol/L, or current
use of lipid lowering medication. Retinopathy status for the worst
eye was clinically graded by an ophthalmologist according to the
Early Treatment Diabetic Retinopathy Study criteria [39].
Participants were only included if they had either no retinopathy,
or blinding retinopathy defined as severe non-proliferative diabetic
retinopathy, proliferative diabetic retinopathy, or clinically
significant macular edema. Nephropathy was defined as the
presence of microalbuminuria (30–300 mg/day) or macroalbu-
minuria (.300 mg/day).
DDAH SNP Selection and Genotyping
Using the tagger program implemented in Haploview 4.0 [40],
tag single nucleotide polymorphisms (SNPs) across DDAH1 and
DDAH2 genes, including the promoter region, were selected on the
basis of linkage disequilibrium patterns observed in the Caucasian
(CEU) samples genotyped as part of the International HapMap
Project [41]. Only SNPs with minor allele frequency greater than
5% in HapMap were considered. Twenty six DDAH1 and 10
DDAH2 tag SNPs (Table 2) which captured all alleles with an r
2 of
at least 0.8 (mean r
2=0.95), were genotyped in all individuals on
the Sequenom iPLEX GOLD chemistry on an Autoflex Mass
Spectrometer at the Australian Genome Research Facility,
Brisbane, Australia.
Measurement of Serum Concentrations of ADMA, SDMA
and Arginine
Serum ADMA concentrations were determined in all partici-
pants [10] by liquid chromatography-tandem mass spectrometry
of the butyl esters on an Applied Biosystems 3200 Q-Trap instru-
ment (Applied Biosystems, Scoresby, Victoria), as described by
Schwedhelm et al [42]. HDeuterated internal standards (98 atom%
2H isotopic purity) were purchased from Cambridge Isotope
Laboratories (Andover, MA) and were L-[
2H7]-arginine for
arginine quantitation and 2,3,3,4,4,5,5-[
2H7]-ADMA for ADMA
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determined as 4.0% at a concentration of 0.48 mmol/L.
Statistical Analyses
Pearson correlation was undertaken for associations of clinical
covariates with ADMA levels in SPSS (v15.0 SPSS Inc, Chicago,
IL). Differences in clinical covariates between patients with and
without diabetic retinopathy were calculated by Student’s t-test or
the chi-square test. ADMA levels were log transformed to
approximate a normal distribution. Genotypic associations for all
SNPs were assessed in PLINK (v1.06) [43]. Dominant, additive,
recessive and genotypic models were considered with respect to
the minor allele. Haplotypic analyses were performed in
accordance with the observed linkage disequilibrium (LD) patterns
in the Caucasian sample in HapMap. Multiple testing of
individual SNPs was adjusted for using the Single Nucleotide
Polymorphism Spectral Decomposition (SNPSpD) method of
Nyholt [44] modified by Li and Ji [45] and Bonferroni correction
was applied to haplotype analyses.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0009462.s001 (0.21 MB
DOC)
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